Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
COSTS AND EXPENSES:    
Research and development $ 3,887,039 $ 4,633,194
General and administrative 2,253,188 1,726,338
Total costs and expenses 6,140,227 6,359,532
LOSS FROM OPERATIONS (6,140,227) (6,359,532)
OTHER INCOME:    
Interest income, net 430 2,362
Total other income, net $ 430 2,362
NET LOSS   $ (6,357,170)
BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.10) $ (0.13)
DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.10) $ (0.13)
Weighted Average Number of Shares Outstanding, Basic 61,101,262 48,139,189
Weighted Average Number of Shares Outstanding, Diluted 61,101,262 48,139,189